このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

The Effect of Sequential Therapy on Alzheimer's Disease

2026年8月17日 更新者:Jinzhou Tian、Dongzhimen Hospital, Beijing

The Effect of Sequential Therapy on Alzheimer's Disease: A Prospective Cohort Study

The goal of this observational study is to learn how Alzheimer's disease changes over time in people at different stages of the disease. It will look at changes in memory and thinking, daily activities, behavior, and traditional Chinese medicine symptom patterns. It will also learn about the outcomes and safety of sequential traditional Chinese medicine treatment based on the stage of Alzheimer's disease. The main questions this study aims to answer are:

  • How do memory and thinking, daily activities, behavior, and traditional Chinese medicine symptom patterns naturally change over time in participants with early-, middle-, and late-stage Alzheimer's disease?
  • How do symptoms and traditional Chinese medicine symptom patterns change together as Alzheimer's disease progresses?
  • Do participants receiving stage-based sequential traditional Chinese medicine treatment have different changes in memory and thinking, daily activities, behavior, and overall disease status?
  • What medical problems or side effects occur during sequential traditional Chinese medicine treatment?

About 600 participants aged 55 to 85 years will take part in this study. Participants will be followed for 12 months.

Participants will:

  • Visit the study center at the start of the study and at 3, 6, 9, and 12 months.
  • Complete assessments of memory and thinking, daily activities, behavior, overall disease status, and traditional Chinese medicine symptoms.
  • Have blood tests and other study examinations.
  • Have their treatment use and medical problems recorded during follow-up.

調査の概要

詳細な説明

Alzheimer's disease has a progressive clinical course, and traditional Chinese medicine theory describes changes in syndrome patterns across different stages of the disease. In the early stage, kidney deficiency is considered the predominant pattern. In the middle stage, phlegm, fire, and blood stasis may become more prominent, while the late stage is characterized by severe qi deficiency. Based on this stage-related evolution, a sequential traditional Chinese medicine approach was developed according to the "syndrome cascade hypothesis." Preliminary clinical observations have suggested potential benefits for cognitive function and overall clinical status, but evidence from prospective multicenter studies remains limited.

This prospective multicenter cohort study has three main objectives. First, it will describe the natural changes in cognitive function, activities of daily living, neuropsychiatric symptoms, and traditional Chinese medicine syndrome patterns across the early, middle, and late stages of Alzheimer's disease. It will also characterize the dynamic relationship between clinical symptoms and traditional Chinese medicine syndrome patterns during disease progression. Second, it will evaluate the clinical outcomes associated with stage-based sequential traditional Chinese medicine therapy, including short- and long-term clinical changes. Third, it will evaluate the safety of sequential traditional Chinese medicine therapy in real-world clinical use.

Treatment exposure will be recorded prospectively. Exposure assessment will consider cumulative medication use, medication adherence, treatment continuity, and treatment interruption. Information from medication dispensing and return records, medication diaries, and investigator follow-up records will be used to assess treatment exposure. The time from the beginning of treatment exposure to subsequent outcome assessment will also be recorded.

General demographic and baseline clinical characteristics will be summarized using descriptive statistics. Continuous outcomes will be analyzed using linear mixed-effects models to evaluate changes over time. The models will include time, exposure status, and the interaction between time and exposure status. Single-time-point comparisons may use independent-samples tests or analysis of covariance, as appropriate. Binary outcomes will be analyzed using logistic regression, with adjustment for potential confounding factors when appropriate.

Prespecified subgroup analyses will explore whether the associations with sequential therapy differ according to disease stage, age, sex, baseline cognitive function, concomitant use of Western medicines, and traditional Chinese medicine syndrome type. Interaction terms between subgroup factors and exposure status will be used to explore differences among subgroups. These subgroup analyses will be considered exploratory.

Missing data patterns will be assessed to determine whether data are missing completely at random, missing at random, or missing not at random. Multiple imputation will be used for missing primary outcomes and key covariates, with variables related to missingness included in the imputation model. Sensitivity analyses will be performed to examine the robustness of the findings under different assumptions and exposure definitions.

研究の種類

観察的

入学 (推定)

600

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100700
        • 募集
        • Dongzhimen Hospital, Beijing University of Chinese Medicine
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

The study population consists of participants with different stages of Alzheimer's disease recruited from Dongzhimen Hospital, Beijing University of Chinese Medicine, and participating study centers. Recruitment settings include brain disease departments, neurology departments, memory clinics, and traditional Chinese medicine outpatient clinics. Participants include individuals with mild cognitive impairment due to Alzheimer's disease and those with mild, moderate, or severe Alzheimer's dementia.

説明

Inclusion Criteria:

  • Age 55 to 85 years, regardless of sex.
  • Memory decline reported by the participant or family member for at least 6 months.
  • Meets the diagnostic criteria for the target disease and is clinically diagnosed with mild cognitive impairment due to Alzheimer's disease or mild, moderate, or severe Alzheimer's dementia.
  • Able to complete clinical scale assessments and blood sampling.
  • Able to undergo brain magnetic resonance imaging (MRI) or amyloid-beta positron emission tomography (Aβ-PET) examinations using the tracers specified in the study protocol.
  • Written informed consent provided by the participant or a legally authorized representative.
  • Able to complete study follow-up.
  • Participants with a known allergy to components of the exposure medications will be assigned to the non-exposed group.

Exclusion Criteria:

  • Cerebrovascular disease, traumatic brain injury, thyroid dysfunction, vitamin deficiency, or other diseases sufficient to cause cognitive impairment.
  • Malignant tumors unrelated to the target disease, hematological diseases, severe psychiatric disorders, depression, or anxiety disorders.
  • Severe dysfunction of major organs, including the heart, brain, liver, or kidneys.
  • Infectious diseases, including HIV or HBV infection.
  • Pregnancy, breastfeeding, or plans for pregnancy in the near future.
  • Gastrointestinal diseases that may affect drug absorption.
  • Use of medications affecting cognitive function within 4 weeks before enrollment.
  • Recent participation in or current participation in another trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Early-Stage AD With Kidney-Tonifying Formula

Participants with early-stage Alzheimer's disease who receive the Kidney-Tonifying Formula and meet the prespecified exposure criteria.

Kidney-Tonifying Formula:Qinggong Shoutao Pills (Daren Tang) contain donkey kidney, deer kidney, dog kidney, ginseng, Tian Dong, Mai Dong, goji berry, Rehmannia root, Dang Gui, salt-processed Yi Zhi, stir-fried Suan Zao Ren, charred Fen Xin Mu, and other ingredients. The prescribed dose is 50 pills (7 g) orally twice daily.

Middle-Stage AD With Kidney-Tonifying and Phlegm-Resolving Formula

Participants with middle-stage Alzheimer's disease who receive the Kidney-Tonifying and Phlegm-Resolving Formula and meet the prespecified exposure criteria.

Kidney-Tonifying and Phlegm-Resolving Formula:Modified Huanshaodan consists of prepared Rehmannia root 10 g, Chinese yam 10 g, Niu Xi 9 g, goji berry 10 g, Shan Zhu Yu 10 g, Poria 15 g, Du Zhong 10 g, processed Yuan Zhi 9 g, Wu Wei Zi 10 g, Shi Chang Pu 3 g, Ba Ji Tian 10 g, Cistanche tubulosa 10 g, ginseng 9 g, and Yu Jin (Guangxi E Zhu) 9 g. One packet is taken orally twice daily.

Late-Stage AD With Kidney-Tonifying and Collapse-Preventing Formula

Participants with late-stage Alzheimer's disease who receive the Kidney-Tonifying and Collapse-Preventing Formula and meet the prespecified exposure criteria.

Kidney-Tonifying and Collapse-Preventing Formula:Modified Yiwang Shuangquandan consists of ginseng 9 g, Qian Shi 15 g, Chinese yam 10 g, Mai Dong 10 g, Wu Wei Zi 10 g, Suan Zao Ren 10 g, Yuan Zhi 6 g, Shi Chang Pu 3 g, Dang Gui 10 g, Sang Piao Xiao 5 g, prepared Rehmannia root 10 g, Shan Zhu Yu 10 g, Huang Qi 5 g, Huang Lian 3 g, Mu Dan Pi 10 g, and Tu Si Zi 10 g. One packet is taken orally twice daily.

Non-Exposed Group
Participants who do not receive the study medication, have medication adherence below 80%, discontinue treatment during follow-up, or do not complete the prespecified follow-up period are classified as the non-exposed group.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)
時間枠:Baseline to Month 12
The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is used to assess overall cognitive and functional impairment. The total score ranges from 0 to 18, with higher scores indicating greater disease severity and a worse outcome. The outcome is the change in CDR-SB score from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog11)
時間枠:Baseline to Month 12
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is used to assess cognitive impairment in participants with early- and middle-stage Alzheimer's disease. The standard 11-item ADAS-Cog total score ranges from 0 to 70, with higher scores indicating greater cognitive impairment and a worse outcome. The outcome is the change in ADAS-Cog score from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Severe Impairment Battery (SIB)
時間枠:Baseline to Month 12
The Severe Impairment Battery (SIB) is used to assess cognitive function in participants with late-stage Alzheimer's disease. The total score ranges from 0 to 100, with higher scores indicating better cognitive function and a better outcome. The outcome is the change in SIB score from baseline to Month 12.
Baseline to Month 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Mini-Mental State Examination (MMSE)
時間枠:Baseline to Month 12
The Mini-Mental State Examination (MMSE) is used to assess cognitive function. The total score ranges from 0 to 30, with higher scores indicating better cognitive function and a better outcome. The outcome is the change in MMSE score from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
時間枠:Baseline to Month 12
The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) is used to assess performance of activities of daily living. The total score ranges from 0 to 78, with higher scores indicating greater independence in daily functioning and a better outcome. The outcome is the change in ADCS-ADL score from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Neuropsychiatric Inventory (NPI)
時間枠:Baseline to Month 12
The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms. The 12-domain total score ranges from 0 to 144, with higher scores indicating more severe neuropsychiatric symptoms and a worse outcome. The outcome is the change in NPI score from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Blood Aβ42/Aβ40 Ratio
時間枠:Baseline to Month 12
The blood amyloid beta 42 to amyloid beta 40 (Aβ42/Aβ40) ratio will be measured at baseline and Month 12. The Aβ42/Aβ40 ratio is a dimensionless value. The outcome is the change in the Aβ42/Aβ40 ratio from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Blood Phosphorylated Tau 181 (P-Tau181)
時間枠:Baseline to Month 12
Blood phosphorylated tau 181 (P-Tau181) will be measured in picograms per milliliter (pg/mL) at baseline and Month 12. The outcome is the change in P-Tau181 concentration from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Blood Phosphorylated Tau 217 (P-Tau217)
時間枠:Baseline to Month 12
Blood phosphorylated tau 217 (P-Tau217) will be measured in picograms per milliliter (pg/mL) at baseline and Month 12. The outcome is the change in P-Tau217 concentration from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Blood Neurofilament Light Chain (NfL)
時間枠:Baseline to Month 12
Blood neurofilament light chain (NfL) will be measured in picograms per milliliter (pg/mL) at baseline and Month 12. The outcome is the change in NfL concentration from baseline to Month 12.
Baseline to Month 12
Change From Baseline in Blood Glial Fibrillary Acidic Protein (GFAP)
時間枠:Baseline to Month 12
Blood glial fibrillary acidic protein (GFAP) will be measured in picograms per milliliter (pg/mL) at baseline and Month 12. The outcome is the change in GFAP concentration from baseline to Month 12.
Baseline to Month 12

その他の成果指標

結果測定
メジャーの説明
時間枠
Incidence of Serious Adverse Events
時間枠:Up to 12 months
The number and proportion of participants experiencing serious adverse events during the study follow-up period.
Up to 12 months
Incidence of Adverse Events
時間枠:Up to 12 months
The number and proportion of participants experiencing adverse events during traditional Chinese medicine use and follow-up. Adverse events include any unfavorable medical events occurring during treatment or follow-up, including symptoms, signs, or laboratory abnormalities, regardless of whether they are considered related to treatment.
Up to 12 months
Change From Baseline in Kidney Deficiency Score Assessed by the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD)
時間枠:Baseline and Months 3, 6, 9, and 12
Kidney deficiency is assessed using the kidney deficiency subscale of the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD). The score ranges from 0 to 21, with higher scores indicating a greater degree of kidney deficiency and therefore a worse pattern outcome. A score of 7 or higher indicates the presence of the kidney deficiency pattern element. The outcome is the change from baseline in the kidney deficiency score at each follow-up assessment.
Baseline and Months 3, 6, 9, and 12
Change From Baseline in Phlegm Obstruction Score Assessed by the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD)
時間枠:Baseline and Months 3, 6, 9, and 12
Phlegm obstruction is assessed using the phlegm obstruction subscale of the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD). The score ranges from 0 to 20, with higher scores indicating a greater degree of phlegm obstruction and therefore a worse pattern outcome. A score of 7 or higher indicates the presence of the phlegm obstruction pattern element. The outcome is the change from baseline in the phlegm obstruction score at each follow-up assessment.
Baseline and Months 3, 6, 9, and 12
Change From Baseline in Fire Disturbance Score Assessed by the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD)
時間枠:Baseline and Months 3, 6, 9, and 12
Fire disturbance is assessed using the fire disturbance subscale of the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD). The score ranges from 0 to 20, with higher scores indicating a greater degree of fire disturbance and therefore a worse pattern outcome. A score of 7 or higher indicates the presence of the fire disturbance pattern element. The outcome is the change from baseline in the fire disturbance score at each follow-up assessment.
Baseline and Months 3, 6, 9, and 12
Change From Baseline in Blood Stasis Score Assessed by the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD)
時間枠:Baseline and Months 3, 6, 9, and 12
Blood stasis is assessed using the blood stasis subscale of the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD). The score ranges from 0 to 20, with higher scores indicating a greater degree of blood stasis and therefore a worse pattern outcome. A score of 7 or higher indicates the presence of the blood stasis pattern element. The outcome is the change from baseline in the blood stasis score at each follow-up assessment.
Baseline and Months 3, 6, 9, and 12
Change From Baseline in Yang Deficiency Score Assessed by the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD)
時間枠:Baseline and Months 3, 6, 9, and 12
Yang deficiency is assessed using the Yang deficiency subscale of the Revised Pattern Elements Scale in Alzheimer's Disease (PES-AD). The score ranges from 0 to 21, with higher scores indicating a greater degree of Yang deficiency and therefore a worse pattern outcome. A score of 7 or higher indicates the presence of the Yang deficiency pattern element. The outcome is the change from baseline in the Yang deficiency score at each follow-up assessment.
Baseline and Months 3, 6, 9, and 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:JinZhou Tian、Dongzhimen Hospital, Beijing

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月30日

一次修了 (推定)

2028年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年8月12日

QC基準を満たした最初の提出物

2026年8月12日

最初の投稿 (実際)

2026年8月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月19日

QC基準を満たした最後の更新が送信されました

2026年8月17日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する